FDA approves Gilead HIV pill Bixlenvo designed to simplify treatment
Gilead Bixlenvo drug Courtesy: Gilead The Food and Drug Administration approved a once-daily HIV pill from Gilead that…
The startup using AI to help build custom treatments for rare diseases
Jacalyn Lee, founder of The DAND Alliance, and her youngest daughter Isla. Jacalyn Lee CNBC Cures is proudly…
AstraZeneca and Bristol Myers Squibb mull $400 billion deal: Report
A smart acquisition strategy has made Bristol-Meyers, which has bought seven companies since October 2007, a big player…
New Medicaid work rules could leave rare disease patients uninsured
CNBC Cures is proudly underwritten by Alexion, AstraZeneca Rare Disease, whose support enables our journalism to elevate stories…
AstraZeneca stock dives 9% after heart drug trial misses target
Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease failed…
Weight loss drug maker stock sinks 25% as safety data spooks investors
Shares of weight loss drug maker Zealand Pharma plummeted as much as 26% on Monday after new data…
AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success
AstraZeneca CEO Pascal Soriot said artificial intelligence is helping drugmakers develop medicines faster and make smarter decisions throughout…
Stock market today: Live updates
Traders work on the floor of the New York Stock Exchange. NYSE Futures linked to the S&P 500…
Reality of Trump’s drug pricing to set in over next 18 months
Novartis‘ CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult…
Eli Lilly to acquire cancer drug maker Kelonia in deal worth up to $7B
Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company…
Trump tariffs fall, but trade war impacts linger
A year after President Donald Trump declared his “liberation day” and imposed sweeping tariffs on imports, kicking off…
Eli Lilly’s lead in the obesity race gets wider after win against Novo
In the lucrative obesity drug race, there is Eli Lilly — and then there’s everybody else. A pair…